Morgan Stanley
NDRM

Morgan Stanley’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Morgan Stanley’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-950
Closed -$37K – 6910
2017
Q3 		$37K Sell
950
-10,132
-91% -$373K ﹤0.01% 5876
2017
Q2 		$332K Sell
11,082
-2,957
-21% -$76.6K ﹤0.01% 5045
2017
Q1 		$373K Sell
14,039
-460
-3% -$11.4K ﹤0.01% 5010
2016
Q4 		$323K Sell
14,499
-605
-4% -$11.3K ﹤0.01% 5156
2016
Q3 		$279K Sell
15,104
-2,578
-15% -$44.7K ﹤0.01% 4847
2016
Q2 		$287K Sell
17,682
-399
-2% -$6.72K ﹤0.01% 4754
2016
Q1 		$256K Sell
18,081
-34,391
-66% -$465K ﹤0.01% 4840
2015
Q4 		$895K Buy
52,472
+18,910
+56% +$368K ﹤0.01% 4136
2015
Q3 		$694K Buy
33,562
+25,467
+315% +$522K ﹤0.01% 4389
2015
Q2 		$125K Buy
8,095
+4,895
+153% +$68.9K ﹤0.01% 5474
2015
Q1 		$43K Sell
3,200
-6,074
-65% -$74.7K ﹤0.01% 5851
2014
Q4 		$130K Buy
+9,274
New +$73.3K ﹤0.01% 5435

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Morgan Stanley's NDRM Position: Q4 2017 in Review

Morgan Stanley sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 950 shares — an estimated $37K sold.

Morgan Stanley first reported a position in NDRM in Q4 2014 and held it in 12 quarters. The position peaked at $895K in Q4 2015. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Morgan Stanley reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Morgan Stanley sold 950 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $37K.
  • Morgan Stanley first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 12 quarters.
  • Morgan Stanley's NeuroDerm Ltd. Ordinary Shares position peaked at $895K in Q4 2015.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.